Press & media

The story

Roughly one in three couples quit IVF before having a baby, and it is rarely because a cycle failed. It is the months of burden between visits, the part of treatment no one supports. Better retention, not new lab technology, is the largest remaining lever on cumulative success. Izana is built to support that gap: clinically governed, vendor neutral, and for both partners.

Key facts, with sources

• 1 in 2 couples do not complete the cycles their clinic recommends, most often from burden, rarely from biology. Shen et al., 2023
• Under 5% of the fertility journey is time inside the clinic; the rest is at home. Wu et al., 2013
• 51 to 72% cumulative live-birth rate over six cycles; the 21-point gap is discontinuation, not biology. Malizia et al., NEJM 2009
• A less burdensome experience roughly halved drop-out in a prospective cohort. Verberg et al., 2008

Whitepapers

Two papers underpin the product, one clinical and one on the market. Both are free:

• The Inter-Cycle Gap (clinical)
• The Cost of Waiting (market)
• Full evidence and citations: izana.ai/research

Clinical advisors

Izana’s science is reviewed by reproductive specialists and a clinical dietician:

• Dr. Atul Ganatra — MBBS, DGO, MD (Obstetrics & Gynaecology) · Past Vice President, FOGSI
• Dr. Vani Sundarapandian — MBBS, MD (Obstetrics & Gynaecology), MRCOG (London) · Reproductive Medicine & Infertility
• Dr. Baiju Ahamed — Embryology
• Nithya — Clinical Dietician

How we research and review content: izana.ai/how-we-review.

Quick facts

• What: a clinically governed fertility companion app for couples and their clinics.
• Model: B2B2C; couples onboard through their fertility clinic.
• Company: registered in Spain, with offices in India.
• Status: live with first partner fertility centres; clinic pilots open.

Brand assets & contact

Logo: izana-horizontal.png. For interviews, data, or anything else, email hello@izana.ai.